ArriVent BioPharma, Inc. Common Stock AVBP
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $44.86 (+197.3% upside)
Key Stats
- Today's Range
- $11.36 – $15.79
- 50-Day Range
- $11.36 – $32.65
- 52-Week Range
- $11.36 – $35.83
- Volume
- 19.75 million shs
- Average Volume
- 1.24 million shs
- Market Cap
- $1.40 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.83
- Price / Sales
- —
Short Interest
- Short Interest
- 0.04%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-163,735,000
- Net Margin
- —
- Return on Equity
- -44.63%
- Debt-to-Equity
- —
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Related Stocks
Compare head-to-head: AVBP vs LLY·AVBP vs JNJ·AVBP vs ABBV·AVBP vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.